US2011172197A1PendingUtilityA1

Dosace Form For Hormonal Contraceptive

49
Assignee: GRUENENTHAL CHEMIEPriority: May 28, 2004Filed: Mar 23, 2011Published: Jul 14, 2011
Est. expiryMay 28, 2024(expired)· nominal 20-yr term from priority
Inventors:Georg SchrammEric-Paul Paques
A61P 5/34A61P 5/30A61K 31/57A61K 31/565A61P 15/18
49
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

A dosage form for hormonal contraception containing a given number of hormone-containing daily units and a given number of hormone-free daily units for daily, oral administration, where the hormone-containing daily units each contain at most the minimum effective daily amount of folic acid for women and the hormone-free daily units contain at least a multiple of this amount up to the maximum permissible amount of folic acid for women.

Claims

exact text as granted — not AI-modified
1 - 15 . (canceled) 
     
     
         16 . A hormonal contraceptive dosage form for uninterrupted daily oral administration to women, said dosage form comprising hormone-containing daily units and hormone-free daily units, wherein each of the hormone-containing daily units does not comprise any folic acid and each of the hormone-free daily units comprises folic acid in a daily amount of >200 μg up to the maximum permissible amount of folic acid for women. 
     
     
         17 . A dosage form according to  claim 16 , wherein the hormone-free daily units each comprises more than 200 μg and up to 5 mg of folic acid. 
     
     
         18 . A dosage form according to  claim 16 , wherein the hormone-free daily units each comprises the same amount of folic acid. 
     
     
         19 . A dosage form according to  claim 16 , wherein the dosage form comprises at least 21 hormone-containing daily units and 7 to 3 hormone-free daily units. 
     
     
         20 . A dosage form according to  claim 19 , wherein the number of hormone-containing daily units is sufficient for administration for a maximum of 2 years, and the number of hormone-free daily units is sufficient for administration for 7 to 3 days. 
     
     
         21 . A dosage form according to  claim 19 , comprising up to 730-hormone-containing daily units and 7 to 3 hormone-free daily units. 
     
     
         22 . A dosage form according to  claim 19 , which comprises 21 to 25 hormone-containing daily units and 7 to 3 hormone-free daily units. 
     
     
         23 . A dosage form according to  claim 19 , which comprises 42 to 52 hormone-containing daily units and 7 to 3 hormone-free daily units. 
     
     
         24 . A dosage form according to  claim 19 , which comprises 77 to 193 hormone-containing daily units and 7 to 3 hormone-free daily units. 
     
     
         25 . A dosage form according to  claim 19 , wherein the dosage form comprises up to 365 hormone-containing daily units and 7 to 3 hormone-free daily units. 
     
     
         26 . A dosage form according to  claim 16 , wherein the hormone-containing daily units each comprises at least one contraceptive active hormone component. 
     
     
         27 . A dosage form according to  claim 26 , wherein the hormone-containing daily units each comprises a hormone-combination consisting of an oestrogen and a gestagen. 
     
     
         28 . A dosage form according to  claim 16 , wherein the hormone-containing daily units correspond to a monophasic contraceptive. 
     
     
         29 . A kit comprising at least one dosage form for hormonal contraception according to  claim 16 . 
     
     
         30 . A kit form according to  claim 29 , wherein the kit comprises a plurality of dosage forms for hormonal contraception according to  claim 16 .

Join the waitlist — get patent alerts

Track US2011172197A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.